Kidney Cancer Clinical Trial
Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI
Summary
Development and validation of a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning
Full Description
Oropharyngeal squamous cell carcinoma (OPSCC) is a rare cancer (incidence ~700 per year in the Netherlands), originating in the middle part of the throat. In OPSCC, nodal status is an important prognostic factor for survival. In the clinical TNM (tumor node metastases) system, nodal status is mainly defined by the size, number and laterality of nodal metastases. In surgically treated patients the pathological TNM classification includes the presence of pathological extranodal extension (pENE). pENE is a predictor for poor outcome and also an indication for the addition of chemotherapy to postoperative radiation. However, most patients with OPSCC are treated non-surgically by means of radiation or chemoradiation and thus information about pENE is lacking. Recently, extranodal extension on diagnostic imaging has been associated with prognosis in OPSCC patients. It is anticipated that in the near future radiological ENE (rENE) may be included in the cTNM classification system for refinement of outcome prediction in patients with nodal disease. The diagnosis of rENE on radiological imaging is new and not trivial and we hypothesize that Artificial Intelligence (AI) may support the radiologist in detecting rENE. In this study we aim to develop and validate a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning
Eligibility Criteria
Inclusion criteria:
Non-metastatic (M0) node-positive HPV+ and HPV- oropharyngeal carcinoma
Treated between 2008 to 2019
Curative intent
Radiation only or concurrent chemoradiation
Modern treatment modality: IMRT / VMAT
diagnostic/staging image scanning protocols available (contrast-enhanced CT with 2-3 mm slice thickness and/or MR with 3 mm slice thickness)
Exclusion criteria:
removal of lymph node (LN) (excisional biopsy or neck dissection [ND]) prior to staging CT/MR scan
no available imaging within 2 months prior to radiotherapy (RT)"
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Boston Massachusetts, 02115, United States
Toronto Ontario, M5G 2, Canada
Maastricht Limburg, 6229 , Netherlands
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.